Acer Therapeutics, Inc. is a pharmaceutical company. The firm engages in the acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded by Christopher Schelling on September 19, 2017 and is headquartered in Newton, MA.
Company profile
Website
CEO
Christopher Schelling
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
320426967
Latest filings (excl ownership)
D
$15.67M in equity, sold $15.67M, 10 investors
4 Oct 17
D
$5.5M in debt / securities to be acquired, sold $3.13M, 4 investors
5 Apr 17
D
$8.15M in equity, sold $8.15M, 6 investors
6 May 16
D/A
$8.15M in equity, sold $8.15M, 6 investors
6 May 16
D
$2.1M in debt / securities to be acquired, sold $2.1M, 2 investors
2 Apr 15
Latest ownership filings